Showing results (131-140 of 172) with videos related to

Sort By:
Pageof 18
International Journal of Rheumatic Diseases|August 18, 2012
Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitisZaiying Hu, Manlong Xu, Qiuxia Li, et al.
Arthritis Research & Therapy|June 21, 2020
TNF-α inhibitor therapy can improve the immune imbalance of CD4+ T cells and negative regulatory cells but not CD8+ T cells in ankylosing spondylitisMingcan Yang, Qing Lv, Qiujing Wei, et al.
International Journal of Rheumatic Diseases|January 29, 2014
An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemiaXinfang Huang, Hui Du, Jieruo Gu, et al.
Rheumatology and Immunology Research|December 5, 2022
2020 Chinese Guidelines for the Diagnosis and Treatment of Systemic Lupus ErythematosusMengtao Li, Yan Zhao, Zhiyi Zhang, et al.
Clinical and Experimental Rheumatology|September 21, 2013
Limitations of lumbar spine MRI in the diagnosis of ankylosing spondylitisZaiying Hu, Manlong Xu, Zhiming Lin, et al.
Arthritis Research & Therapy|September 7, 2024
A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)Xiaomei Leng, Piotr Leszczyński, Slawomir Jeka, et al.
Frontiers in Pharmacology|March 27, 2020
Circulating Retinol-Binding Protein 4 as a Possible Biomarker of Treatment Response for Ankylosing Spondylitis: An Array-Based Comparative StudyJialing Wu, Xinyu Wu, Zena Chen, et al.
Frontiers in Immunology|June 15, 2026
Predicting major organ complications in primary Sjögren's disease using a machine learning ensemble strategy: a dual-center retrospective clinical studyWenqi Xia, Jiayun Wu, Jingyu Zhang, et al.
RMD Open|April 16, 2022
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 yearsFengchun Zhang, Jie Zheng, Yang Li, et al.
Frontiers in Immunology|September 12, 2022
Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trialLiudan Tu, Minjing Zhao, Xiaohong Wang, et al.
Pageof 18